Chat with us, powered by LiveChat

How to better anticipate and mitigate adverse drug reactions [an infographic]

Are you interested in collaboratively using data to predict and avoid adverse drug reactions? The Effiris consortium – currently composed of Takeda, GSK and UCB – is working to achieve just that.

The project aims to help pharmaceutical organisations accelerate drug discovery through machine learning.

Many readers will be very familiar with the fact that one of the biggest challenges in building accurate predictive models within the pharmaceutical drug discovery space, is the limited availability of high-quality data, due to the often-confidential nature of the data. The Effiris privacy preserving data sharing methodology aims to overcome this obstacle.

Read more about the Effiris approach and progress in the infographic below.

anticipating and mitigating adverse drug reactions through machine learning and privacy preserving data sharing

________________

Did you enjoy this blog? Please let us know.

What else would you like us to write about? Please let us know.

Last Updated on January 25, 2024 by lhasalimited

You may also like

In a recent Lhasa Limited webinar, experts from BfR (the German Federal Institute for Risk Assessment), Syngenta, and Lhasa came together to …

The Science of Stability (SoS) 2025 conference, recently held in Philadelphia, brought together leading experts from the pharmaceutical industry and academia. Co-hosted by Lhasa Limited and …

The ICH M7(R2) Guideline (2023) continues to recommend the bacterial reverse mutation assay (Ames test), conducted in accordance with OECD 471, as …